2028 applied to be registered as an	importer of the following basic classes of controlled substances:		
	Controlled substance	Drug code	Schedule
Remifentanil		9739	II

The company plans to import the listed controlled substance for bulk manufacture.

Dated: October 23, 2019. William T. McDermott, Assistant Administrator. [FR Doc. 2019–25403 Filed 11–21–19; 8:45 am] BILLING CODE 4410–09–P

### DEPARTMENT OF JUSTICE

#### Drug Enforcement Administration

[Docket No. DEA-538]

## Importer of Controlled Substances Application: GE Healthcare

## **ACTION:** Notice of application.

**DATES:** Registered bulk manufacturers of the affected basic classes, and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before December 23, 2019. Such persons may also file a written request for a hearing on the application on or before December 23, 2019.

ADDRESSES: Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152. All requests for a hearing must be sent to: Drug Enforcement Administration, Attn: Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152. All requests for a hearing should also be sent to: (1) Drug Enforcement Administration, Attn: Hearing Clerk/OALJ, 8701 Morrissette Drive, Springfield, Virginia 22152; and (2) Drug Enforcement Administration, Attn: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152.

**SUPPLEMENTARY INFORMATION:** In accordance with 21 CFR 1301.34(a), this is notice that on July 15, 2019, GE Healthcare, 3350 North Ridge Avenue, Arlington Heights, Illinois 60004–1412 applied to be registered as an importer of the following basic class of controlled substance:

Controlled substance	Drug code	Schedule
Cocaine	9041	II

The company plans to import small quantities of Ioflupane, in the form of three separate analogues of cocaine, to validate production and quality control systems, for a reference standard, and for producing material for a future investigational new drug (IND) submission. Supplies of this particular controlled substance are not available in the form needed within the current domestic supply of the United States. Dated: November 7, 2019. William T. McDermott, Assistant Administrator. [FR Doc. 2019–25404 Filed 11–21–19; 8:45 am] BILLING CODE 4410–09–P

## DEPARTMENT OF JUSTICE

### **Drug Enforcement Administration**

[Docket No. DEA-529]

### Bulk Manufacturer of Controlled Substances Application: Patheon API Manufacturing, Inc.

**ACTION:** Notice of application.

**DATES:** Registered bulk manufacturers of the affected basic classes, and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before January 21, 2020.

**ADDRESSES:** Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152.

## SUPPLEMENTARY INFORMATION: ${\rm In}$

accordance with 21 CFR 1301.33(a), this is notice that on March 15, 2019, Patheon API Manufacturing, Inc., 309 Delaware Street, Greenville, South Carolina 29605 applied to be registered as a bulk manufacturer of the following basic classes of controlled substances:

Controlled substance	Drug code	Schedule
Thebaine	9333	11
Noroxymorphone	9668	II
Gamma Hydroxybutyric Acid	2010	1
Alpha-methyltryptamine	7432	I

The company plans to bulk manufacture the listed controlled substances as an Active Pharmaceutical Ingredient for supply to its customers.

Dated: November 5, 2019.

William T. McDermott,

Assistant Administrator.

[FR Doc. 2019–25401 Filed 11–21–19; 8:45 am] BILLING CODE 4410–09–P

### DEPARTMENT OF JUSTICE

#### Drug Enforcement Administration

[Docket No. DEA-545]

Bulk Manufacturer of Controlled Substances Application: S&B Pharma, Inc.

**ACTION:** Notice of application.

**DATES:** Registered bulk manufacturers of the affected basic classes, and

applicants therefore, may file written comments on or objections to the issuance of the proposed on or before January 21, 2020.

**ADDRESSES:** Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152.

## SUPPLEMENTARY INFORMATION: ${ m In}$

accordance with 21 CFR 1301.33(a), this

is notice that on October 4, 2019, S & B Pharma, Inc., DBA Norac Pharma, 405

South Motor Avenue, Azusa, California 91702–3232 applied to be registered as

a bulk manufacturer of the following basic classes of controlled substances:

Controlled substance	Drug code	Schedule
Gamma Hydroxybutyric Acid	7360	1
Telrahydrocannabinois	7370	I
Amphetamine	1100	11
Methamphetamine	1105	11
Lisdexamfetamine	1205	11
Methylphenidate	1724	11
Pentobarbital	2270	11
4-Anilino-N-phenethyl-4-piperidine (ANPP)	8333	11
Tapentadol	9780	11
Fentanyl	9801	11

The company plans to manufacture the listed controlled substances in bulk for use in product development and for commercial sales to its customers. In reference to drug code 7360 (marihuana) and 7370 (tetrahydrocannabinois), the company plans to bulk manufacture both as synthetic substances. No other activity for these dug codes is authorized for this registration.

Dated: November 5, 2019.

# William T. McDermott,

Assistant Administrator. [FR Doc. 2019–25402 Filed 11–21–19; 8:45 am]

# BILLING CODE 4410-09-P

### DEPARTMENT OF JUSTICE

Drug Enforcement Administration [Docket No. DEA-549]

## Importer of Controlled Substances Application: Mylan Technologies Inc.

**ACTION:** Notice of application.

DATES: Registered bulk manufacturers of the affected basic classes, and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before December 23, 2019. Such persons may also file a written request for a hearing on the application on or before December 23, 2019. ADDRESSES: Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152. All requests for a hearing must be sent to: Drug Enforcement Administration, Attn: Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152. All requests for a hearing should also be sent to: (1) Drug Enforcement Administration, Attn: Hearing Clerk/OALJ, 8701 Morrissette Drive, Springfield, Virginia 22152; and (2) Drug Enforcement Administration, Attn: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152.

**SUPPLEMENTARY INFORMATION:** In accordance with 21 CFR 1301.34(a), this is notice that on October 16, 2019, Mylan Technologies Inc., 110 Lake Street, Saint Albans, Vermont 054780 applied to be registered as an importer of the following basic classes of controlled substances:

Controlled substance	Drug code	Schedule
Methylphenidate	1724	
Fentanyl	9801	

The company plans to import the listed controlled substances in finished dosage form (FDF) from foreign sources for analytical testing and clinical trials in which the foreign FDF will be compared to the company's own domestically-manufactured FDF. This analysis is required to allow the company to export domestically manufactured FDF to foreign markets.

Dated: November 8, 2019.

William T. McDermott,

Assistant Administrator.

[FR Doc. 2019–25405 Filed 11–21–19; 8:45 am] BILLING CODE 4410–09–P

#### DEPARTMENT OF JUSTICE

**Drug Enforcement Administration** 

[Docket No. DEA-540]

## Bulk Manufacturer of Controlled Substances Application: Chattem Chemicals

**ACTION:** Notice of application.

**DATES:** Registered bulk manufacturers of the affected basic classes, and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before January 21, 2020.

ADDRESSES: Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152.

**SUPPLEMENTARY INFORMATION:** In accordance with 21 CFR 1301.33(a), this is notice that on May 17, 2019, Chattem Chemicals, 3801 Saint Elmo Avenue, Chattanooga, Tennessee 37409 applied to be registered as a bulk manufacturer of the following basic classes of controlled substances:

Controlled substance	Drug code	Schedule
Gamma Hydroxybutyric Acid	2010	I
Marihuana	7360	
Tetrahydrocannabinols	7370	I